Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B; 02496) disclosed its monthly return update for the period ended 28 February 2026. According to the announcement, the company’s total authorised and registered share capital remained at RMB 193.85 million. This comprises 111.47 million H shares, 75.51 million domestic shares, and 6.87 million unlisted foreign shares, with no change from the previous month.

The H shares remain in compliance with the applicable minimum public float requirement of 25%. Additionally, a 2024 H Share Option Plan adopted on 27 June 2024 shows 1.25 million share options outstanding at period-end. Meanwhile, the conversion of 68.01 million unlisted shares to H shares was approved, and the process is still ongoing. No other changes or movements in issued share capital and treasury shares were disclosed during the period.